Selection of a Lead Long-Acting Formulation of Ivermectin to Target Major Malaria Vectors in Western Africa: Evaluation of Pharmacokinetics and Mosquitocidal Efficacy in Cattle under Laboratory Conditions.

This study identifies mdc-STM-001, a long-acting injectable ivermectin formulation, as the lead candidate for malaria control in Western Africa because it demonstrates a favorable pharmacokinetic profile and sustained efficacy in killing pyrethroid-resistant *Anopheles* mosquitoes for at least two months following a single cattle injection.

The Gist

The Big Picture: A New Shield Against Malaria

Imagine malaria as a relentless army of tiny, invisible assassins (mosquitoes) that strike at night. For decades, we've fought them with two main weapons: nets (to block them from entering houses) and sprays (to kill them on the walls).

But the mosquitoes are getting smarter. They are evolving to bite earlier in the day, outside of houses, or even developing a "superpower" that makes the sprays useless. We need a new strategy.

Enter Ivermectin. Think of this drug as a "poisoned honey." When a person (or animal) takes it, their blood becomes toxic to the mosquitoes that try to bite them. If a mosquito takes a sip of this blood, it dies before it can pass on malaria.

The Problem: The current version of this "poisoned honey" is like a flashlight with weak batteries. It works for a few days, but then the battery dies, and the mosquitoes are safe again. To keep the light on, you have to keep changing the batteries (taking pills every few weeks), which is hard to manage for millions of people.

The Goal: The scientists in this paper wanted to invent a long-lasting lantern—a single injection that keeps the "poisoned honey" flowing in the blood for months, not just days.

---

The Experiment: Testing the Lanterns on Cattle

Since they couldn't test these new "super-injections" on humans yet (safety first!), they used a clever proxy: cattle.

Think of the cattle as test dummies or practice targets. In the wild, malaria mosquitoes often bite cows when they can't find humans. The scientists injected three different versions of this long-lasting Ivermectin into calves in Burkina Faso.

They had three different "recipes" for the injection:

1. Recipe A (mdc-STM-001)
2. Recipe B (mdc-STM-002)
3. Recipe C (mdc-STM-003) (tested at two different strengths)

They also had a group of calves that got no injection (the control group) to see what happens naturally.

The "Mosquito Tasting" Test

Over the next four months, the scientists played a game of "mosquito roulette."

• They took mosquitoes from two groups: KIS (the "normal" mosquitoes that are easily killed) and VK5 (the "tough" mosquitoes that are resistant to normal insecticides).
• They let these mosquitoes bite the treated calves.
• They watched to see how many mosquitoes died within 10 days.

Why 10 days? This is the "incubation period." It takes about 10 days for the malaria parasite to grow inside a mosquito and become ready to infect a human. If the mosquito dies before day 10, the malaria cycle is broken. It's like catching a burglar before they can steal the jewels.

The Results: Finding the Winner

Here is how the three recipes performed:

• Recipe B (mdc-STM-002): This was the underperformer. It was like a flashlight that flickered and died too soon. The mosquitoes started surviving after a few weeks.
• Recipe C (mdc-STM-003): This was a strong contender, especially at the higher dose. It worked well, but it was a bit unpredictable. Sometimes it worked great; other times, the levels in the blood varied too much between different cows.
• Recipe A (mdc-STM-001): This was the champion.
  • Steady Stream: It released the drug at a perfect, steady pace. It didn't have a huge spike at the beginning (which could be dangerous) and didn't drop off too quickly.
  • Longevity: It kept the blood toxic enough to kill mosquitoes for at least 90 days (3 months).
  • Consistency: It worked the same way on every single cow.
  • The Tough Test: It even killed the "tough" (resistant) mosquitoes, which is a huge deal.

The "Goldilocks" Conclusion

The scientists concluded that Recipe A (mdc-STM-001) is the "Goldilocks" formulation. It wasn't too hot (dangerous), wasn't too cold (ineffective), but was just right.

• One shot, three months of protection.
• It works against both the weak and the super-resistant mosquitoes.
• It is safe for the animals (no weight loss, no major side effects).

What Does This Mean for Humans?

This study is a massive step forward. It proves that this new technology works in a living, breathing animal.

• The Next Step: The scientists are now ready to test this "perfect lantern" on humans in Phase 1 clinical trials.
• The Dream: Imagine a world where, instead of taking pills every month, a community gets a single injection once a year (or twice). For the next 3 months, anyone who gets bitten by a mosquito would kill the mosquito before it can spread malaria.
• The Impact: This could be the key to stopping malaria in areas where mosquitoes have learned to dodge our nets and sprays. It's a way to fight the enemy on their own terms, by turning the host (the human) into a deadly trap for the mosquito.

In short: They found a "magic bullet" injection that keeps mosquitoes away for months. If it works in humans like it did in cows, it could be a game-changer in the fight against malaria.

Technical Summary

1. Problem Statement

Malaria remains a critical global health burden, with progress stalled in recent years due to the emergence of insecticide resistance (both physiological and behavioral) in Anopheles mosquito vectors. Current vector control tools, such as insecticide-treated nets (ITNs) and indoor residual spraying (IRS), primarily target indoor-biting mosquitoes and are increasingly bypassed by vectors that feed outdoors or at different times.

Mass Drug Administration (MDA) of oral ivermectin has been proposed as a complementary strategy. Ivermectin is an endectocide that kills mosquitoes feeding on treated hosts. However, standard oral formulations have a short half-life in humans, resulting in mosquitocidal blood concentrations lasting fewer than 7 days. This necessitates frequent, repeated dosing to maintain efficacy, which poses logistical challenges and reduces population coverage. The World Health Organization (WHO) has defined Preferred Product Characteristics (PPC) for endectocides, requiring a Hazard Ratio (HR) > 4 for at least one month post-treatment to effectively interrupt transmission. There is an urgent need for a Long-Acting Injectable Formulation (LAIF) of ivermectin that can sustain lethal blood concentrations for extended periods (ideally >30 days) with a single administration.

2. Methodology

The study utilized a cattle-mosquito model under controlled laboratory conditions in Bobo-Dioulasso, Burkina Faso, to evaluate three candidate LAIFs developed using BEPO® technology (a bioresorbable polymeric depot system).

• Formulations Tested: Three candidates (mdc-STM-001, mdc-STM-002, mdc-STM-003) were tested.
  • mdc-STM-001 and mdc-STM-002 were tested at 0.6 mg/kg.
  • mdc-STM-003 was tested at two doses: 0.6 mg/kg and 1.5 mg/kg (the latter representing the upper limit of feasible subcutaneous volume for humans).
  • A control group received no treatment.
• Subjects: 25 male calves (n=5 per group) were injected subcutaneously.
• Mosquito Colonies: Two strains were used to assess efficacy against resistance:
  • KIS: Anopheles gambiae (fully susceptible to insecticides).
  • VK5: Anopheles coluzzii (wild-derived, pyrethroid-resistant, collected from an irrigated area in Burkina Faso).
• Experimental Design:
  • Pharmacokinetics (PK): Plasma samples were collected over 130+ days to measure ivermectin concentrations. Non-compartmental analysis was used to determine $C_{max}$, $T_{max}$, AUC, and half-life.
  • Mosquitocidal Efficacy: Direct skin-feeding assays were conducted at 15 timepoints (Days 2 to 126 post-injection). Mosquitoes fed on treated calves were monitored for 10 days to assess mortality.
  • Metrics: Efficacy was evaluated using 10-day cumulative mortality, Hazard Ratios (HR), Median Survival Times (MST), and the duration of exposure above the 10-day LC50 (lethal concentration for 50% of the population).

3. Key Contributions

• First-in-Class Evaluation: This is the first study to evaluate candidate long-acting injectable ivermectin formulations specifically designed for human malaria control in a preclinical cattle model.
• Comprehensive PK/PD Correlation: The study rigorously linked pharmacokinetic profiles (plasma concentration) with pharmacodynamic outcomes (mosquito mortality) across both susceptible and resistant vector strains.
• Selection of a Clinical Candidate: The research successfully identified mdc-STM-001 as the optimal formulation for progression to Phase 1 clinical trials based on a multi-criteria decision framework (efficacy, safety, variability, and duration).
• Resistance Validation: The study demonstrated that the selected formulation maintains efficacy against pyrethroid-resistant An. coluzzii, addressing a critical gap in current vector control.

4. Key Results

Pharmacokinetics (PK):

• mdc-STM-001 exhibited the most favorable profile. It showed a controlled peak concentration ($C_{max} \approx 34.5$ ng/mL) with the lowest inter-individual variability (12%) compared to other formulations (which ranged from 41% to 72%).
• It maintained steady plasma levels for an extended period, with a terminal half-life ($T_{1/2}$) of approximately 33 days.
• The formulation achieved sustained concentrations above the lethal threshold for the entire study duration (132 days).

Mosquitocidal Efficacy:

• Mortality Rates: mdc-STM-001 induced >75% mortality in susceptible (KIS) mosquitoes and >50% mortality in resistant (VK5) mosquitoes for at least 60 days post-injection.
• Hazard Ratios (HR): The formulation maintained an HR > 4 (the WHO target) for 70 days against both strains, significantly outperforming mdc-STM-002 (which dropped below HR 4 after ~40 days).
• Survival Time: Median survival times for mosquitoes feeding on mdc-STM-001 treated calves remained below the 10-day extrinsic incubation period (EIP) of Plasmodium falciparum for 90 days in resistant strains and nearly 100 days in susceptible strains.
• LC50 Coverage: The 10-day LC50 for resistant mosquitoes (3.66 ng/mL) was maintained for the entire study duration (≥126 days) with mdc-STM-001.

Safety and Tolerability:

• All formulations were well-tolerated. The primary local reaction was swelling (expected with depot technology), and no systemic adverse events or unscheduled deaths occurred.
• Weight gain in treated calves was comparable to controls.

5. Significance and Conclusion

The study identifies mdc-STM-001 as the optimal candidate for human clinical development. A single subcutaneous injection of this formulation provides sustained mosquitocidal efficacy for at least two months, meeting and exceeding the WHO's minimum target of one month (HR > 4).

• Impact on Transmission: By keeping mosquito lifespans below the 10-day EIP for extended periods, this intervention has the potential to drastically reduce the proportion of infectious mosquitoes, thereby interrupting malaria transmission even in areas with high insecticide resistance and outdoor biting behaviors.
• Strategic Advantage: Unlike oral regimens requiring multiple doses, a single injection offers significant logistical advantages for Mass Drug Administration campaigns, potentially improving coverage and adherence.
• Next Steps: The favorable safety profile and robust entomological data support the progression of mdc-STM-001 to Phase 1 clinical trials in humans. The authors emphasize that while extrapolation from cattle to humans requires caution, the established safety of ivermectin and the consistency of the PK/PD relationship provide a strong rationale for further development.

This work represents a pivotal step toward deploying a novel, long-acting tool to combat residual malaria transmission in sub-Saharan Africa.